Topics:

DaunoXome Available for Advanced HIV-Related KS

DaunoXome Available for Advanced HIV-Related KS

BOULDER, Colorado--NeXstar Pharmaceuticals, Inc., has launched DaunoXome, its liposomal dauno-rubicin product, as first-line treatment for advanced HIV-associated Kaposi's sarcoma (KS).

The FDA approved the agent in April, following review of the company's phase III clinical trial comparing DaunoXome with the ABV regimen (Adriamycin, bleomycin, vincristine).

The liposomal formulation had comparable efficacy (25% response rate vs 28% for ABV), the company said, with major safety advantages, including no significant alopecia, neuropathy, or cardiomyopathy.

"The drug is so well tolerated that patients don't mind coming back every other week for their treatment," said Dr. Jim Wernz, of New York University, at a press briefing.

 
Loading comments...
Please Wait 20 seconds or click here to close